KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Other Non-Current Liabilities (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Other Non-Current Liabilities for 17 consecutive years, with $199.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 12.36% to $199.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $199.1 million, a 12.36% increase, with the full-year FY2025 number at $199.1 million, up 12.36% from a year prior.
  • Other Non-Current Liabilities was $199.1 million for Q4 2025 at Bio-Rad Laboratories, down from $207.5 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $228.9 million in Q1 2021 to a low of $173.1 million in Q1 2025.
  • A 5-year average of $196.4 million and a median of $195.9 million in 2022 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: surged 32.1% in 2021, then dropped 21.31% in 2022.
  • Bio-Rad Laboratories' Other Non-Current Liabilities stood at $182.2 million in 2021, then grew by 7.53% to $195.9 million in 2022, then dropped by 0.47% to $195.0 million in 2023, then decreased by 9.13% to $177.2 million in 2024, then grew by 12.36% to $199.1 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Other Non-Current Liabilities are $199.1 million (Q4 2025), $207.5 million (Q3 2025), and $209.6 million (Q2 2025).